(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 2 June 2005 (02.06.2005)

PCT

(10) International Publication Number WO 2005/049031 A1

- (51) International Patent Classification7: A61K 31/498, 31/513, 31/7068, A61P 35/00
- (21) International Application Number:

PCT/GB2004/050026

(22) International Filing Date:

15 November 2004 (15.11.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/519,690 13 November 2003 (13.11.2003) US

- (71) Applicant (for all designated States except US): PHARMA MAR, S.A.U. [ES/ES]; Polígono Industrial La Mina, Avda. de los Reyes, 1, Colmenar Viejo, E-28770 Madrid (ES).
- (71) Applicant (for SD only): RUFFLES, Graham, Keith [GB/GB]; 66-68 Hills Road, Cambridge, Cambridgeshire CB2 1LA (GB).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): RYBAK, Mary, Ellen [US/US]; 3 Stout Road, Princeton, NJ 08540 (US).

- (74) Agent: Marks & Clerk; 66-68 Hills Road, Cambridge, Cambridgeshire CB2 1LA (GB).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMBINATION

(57) Abstract: Methods of treating a human body for cancer are provided. In one aspect, a therapeutic amount of capecitabine is administered in combination with ET-743 in a dose range between 0.75 and 1.4 mg/m² for Et-743. In a related aspect, an effective therapeutic amount of ET-743 is administered in combination with capecitabine in a dose range between 1500 to 2500 mg/m/day for capecitabine.

